TELA Bio, Inc.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

TELA$0.86+5.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	TELA BIO, INC.

	By:	/s/ ANTONY KOBLISH
		Name: Antony Koblish
		Title: Chief Executive Officer and DirectorDate: March 25, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/ ANTONY KOBLISH	Chief Executive Officer and Director (Principal Executive Officer)	March 25, 2026
Antony Koblish

/s/ ROBERTO CUCA	Chief Operating Officer and Chief Financial Officer(Principal Financial Officer)	March 25, 2026
Roberto Cuca

/s/ MEGAN SMEYKAL	Chief Accounting Officer and Controller (Principal Accounting Officer)	March 25, 2026
Megan Smeykal

/s/ DOUG EVANS	Chairman, Board of Directors	March 25, 2026
Doug Evans

/s/ KURT AZARBARZIN	Director	March 25, 2026
Kurt Azarbarzin

/s/ VINCE BURGESS	Director	March 25, 2026
Vince Burgess

/s/ FEDERICA O’BRIEN	Director	March 25, 2026
Federica O’Brien

/s/ WILLIAM PLOVANIC	Director	March 25, 2026
William Plovanic

/s/ BETTY JO ROCCHIO	Director	March 25, 2026
Betty Jo Rocchio

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.